We do not earn a commission from this provider.
Zera Health review
Graded on whether a price is published, checkable, and still true at month two — how we grade · how we verify prices
Zera Health advertises tirzepatide from $199 a month on its catalog page. The plan block on the drug's own page offers $255 or $215, and nothing in between.
The catalog page prints $199 per month. The tirzepatide page labels $199 a first-month rate and then offers $255 monthly or $215 quarterly, so the advertised figure is not a rate you can stay on.
- Advertised $199, actually $255
- Month-to-month price published
- States not published
- Prices read September 2026
Read first-hand, not from a feed.
Distinct plans priced.
Added by the time you're billed.
This link pays us nothing. It's here because the price is checkable.
The verdict
Every treatment page labels its headline a first-month rate. The catalog page reprints the same figures as monthly rates and drops the word first.
This link pays us nothing. It's here because the price is checkable.
Quick facts
Key facts
- Semaglutide
- $179 monthly, $149 quarterly
- Tirzepatide
- $255 monthly, $215 quarterly
- NAD+
- $130 monthly, $110 quarterly
- Sermorelin
- $155 monthly, $130 quarterly
- Catalog page prices
- $199, $99 and $125 are first-month rates
- Sale end date
- July 1 on one page, October 1 on another
- Legal entity
- Not named on any page we read
- Compounding pharmacy
- Named in the footer of every page
Pros and cons
What we like
- Each treatment page shows a monthly rate and a quarterly rate side by side, with the vial strength attached to both.
- The headline on every treatment page is explicitly labeled a first-month figure, which is more disclosure than most of this market manages.
- The compounding pharmacy is named by company in the footer of every page, including its own website.
- The price is stated to hold flat as the dose goes up, which is a real commitment and not a common one.
- Compounded status and the FDA's non-evaluation of it are stated on the treatment pages and in the footer.
What could be better
- The catalog page strips the word first from four headline prices, turning first-month rates into apparent monthly ones.
- For tirzepatide, NAD+ and sermorelin, the advertised figure matches neither the monthly nor the quarterly plan.
- The same sitewide sale banner carries two different end dates on two pages, one of them already past.
- No legal entity, officer or street address is published on any of the eight pages we read.
- The 50-state claim is a sentence inside a collapsed FAQ with no list behind it.
What it is
A cash-pay catalog with fifteen products: compounded semaglutide and tirzepatide, an oral GLP-1, a microdose plan, NAD+ by injection and nasal spray, sermorelin, MIC and B12, testosterone, ED drugs and hormone therapy. It names its compounding pharmacy, which most sellers do not.
What it does not name is itself. Across eight pages, including the terms, the privacy policy and the telehealth notice, no incorporated company, officer or street address appears — only a first name, an email address and a Florida phone number.
Every price we found
| Plan | Advertised | What you actually pay | The gap | Read on |
|---|---|---|---|---|
| Compounded semaglutide, billed monthlyThe catalog figure against the month-to-month rate. A 2.5 mg or 5 mg vial. | $149 | $179 | September 2026 | |
| Compounded semaglutide, billed quarterlyA month, billed every three months. The one product whose advertised figure it matches. | not published | $149 | not comparable | September 2026 |
| Compounded tirzepatide, billed monthlyThe catalog figure against the month-to-month rate. A 5 mg or 10 mg vial. | $199 | $255 | September 2026 | |
| Compounded tirzepatide, billed quarterlyA month, billed every three months. Still above the $199 the catalog advertises. | not published | $215 | not comparable | September 2026 |
| NAD+, billed monthlyThe catalog figure against the month-to-month rate. A 250 mg vial. | $99 | $130 | September 2026 | |
| NAD+, billed quarterlyA month, billed every three months. | not published | $110 | not comparable | September 2026 |
| Sermorelin, billed monthlyThe catalog figure against the month-to-month rate. A 3 mg or 6 mg vial. | $125 | $155 | September 2026 | |
| Sermorelin, billed quarterlyA month, billed every three months. | not published | $130 | not comparable | September 2026 |
| Oral GLP-1 tablet and microdose planCatalog figures only, at $169 and $129 a month. We did not find a plan block for either. | $169 | not published | not comparable | September 2026 |
This link pays us nothing. It's here because the price is checkable.
What it actually costs
On the semaglutide page: from $149 per first month, then $179 billed monthly or $149 billed every three months. Tirzepatide: from $199 per first month, then $255 monthly or $215 quarterly. NAD+: from $99, then $130 or $110. Sermorelin: from $125, then $155 or $130.
The catalog page reprints those first-month figures as $149, $199, $99 and $125 per month. For three of the four, that number is not a rate the plan block offers at all.
Semaglutide is the exception, and only by coincidence: its quarterly rate happens to equal its first-month rate. This is the starting-at problem in its cleanest form — the product page discloses honestly and the page in front of it does not.
A 40 percent off banner runs sitewide. On the treatment pages it says the sale ends July 1; on the catalog page it says October 1. Both were read the same day.
Who it's wrong for
- Skip it if you are budgeting from the catalog page. Open the drug's own page and read the plan block, which is where the rate you keep paying lives.
- Skip it if you want to know who you are buying from. Eight pages, no company name, no address — and a company we can identify is the baseline we grade against.
- Skip it if you want an FDA-approved pen. Everything priced here is compounded, so the brand-versus-compounded trade-off applies in full.
- Treat the 50-state claim carefully. It is a sentence in a collapsed FAQ with no list attached, unlike a seller that publishes two prices and no state list at all.
How Zera Health works
Two-minute assessment
A short questionnaire rather than an appointment. The site advertises same-day approvals.
A physician reviews it
The footer states that the company is a technology platform, not a medical provider, and that prescribing is the clinician's decision.
The pharmacy ships in 48 hours
The named compounding pharmacy fills the prescription. Shipping is free and included in the plan price.
Medications available
- Compounded semaglutideCompounded$179 monthly or $149 quarterly
A 2.5 mg or 5 mg vial. The first month is advertised at $149.
- Compounded tirzepatideCompounded$255 monthly or $215 quarterly
A 5 mg or 10 mg vial. The catalog advertises $199, which is the first month only.
- NAD+Compounded$130 monthly or $110 quarterly
Sold as an injection and separately as a nasal spray, both listed at $99 on the catalog.
- SermorelinCompounded$155 monthly or $130 quarterly
Injection or oral dissolving tablet. The catalog advertises $125.
- MIC and B12 injectionsCompoundedFrom $69 a month
A catalog figure. We did not find a plan block breaking it into monthly and quarterly rates.
Pharmacy, prescribers and safety checks
- Legal entityNot named on any of the eight pages we read
- Mailing addressNot disclosed
- Compounding pharmacyNamed by company in the footer of every page
- Who prescribesLicensed clinicians; the platform states it is not a provider
- Compounded statusStated as not FDA-approved on the treatment pages
- States servedAll 50 claimed in a collapsed FAQ, with no list
- FDA warning-letter screenNo claim made; see how we reviewed this
Common questions
How much is tirzepatide at Zera Health?
$255 a month billed monthly, or $215 a month billed every three months. The catalog page advertises $199, which the drug's own page labels a first-month rate.
Is the $99 NAD+ price real?
It is a first-month rate. The NAD+ page then offers $130 billed monthly or $110 billed quarterly, so $99 is not a rate you can stay on after the first month.
Which price should I plan around?
The plan block on the drug's own page, not the catalog. The catalog reprints first-month figures as monthly ones by dropping the word first from the label.
Who owns Zera Health?
The site does not say. Across eight pages, including the terms, the privacy policy and the telehealth notice, no incorporated entity, officer or street address is published.
Is Zera Health available in my state?
A collapsed FAQ says the company operates across all 50 states with licensed providers in every state. No enumerated list appears anywhere we read.
Why we gave Zera Health a C
Read the full grading rationale
Every treatment page here does the right thing and the catalog page in front of them undoes it. On the product pages the headline figure is labeled per first month and a plan block underneath gives the two rates that follow, monthly and quarterly. On the catalog page the same figures are relabeled per month with the word first dropped: semaglutide from $149, tirzepatide from $199, NAD+ from $99, sermorelin from $125. For three of those four, the advertised figure is not a rate the plan block offers at all — tirzepatide runs $255 or $215, NAD+ runs $130 or $110, sermorelin runs $155 or $130. Only semaglutide reconciles, because its quarterly rate happens to equal its first-month rate. The same 40 percent off banner shows two different expiry dates on two pages of the same site, one of them a date that has already passed. Zera also names no incorporated entity, no officer and no street address on any of the eight pages we read, including its terms, its privacy policy and its telehealth notice — the only company detail published is a first name, an email address and a Florida phone number. Its compounding partner is named, which is more than most disclose. FDA warning-letter screen on the Zera Health domain: the query returned 0 candidate letters with the positive and negative controls passing in the same run, but the company publishes no address anywhere we read, so the address half of the match was never exercisable and this absence is the weaker kind.
How we reviewed Zera Health
- We read four treatment pages and the catalog page that links them, which is the only way the mismatch is visible — each page on its own is internally consistent.
- Every figure here is quoted from the block it was read in, and the first-month labels are reproduced as the pages print them.
- One FAQ control was opened on a fresh page load to read the state answer.
- We looked for a legal entity on the terms, the privacy policy and the telehealth notice and found none, so this review carries no entity record rather than presenting a brand name as one.
- We screened the domain against the FDA warning-letter database and the query returned no candidate letters, with the known-positive control passing in the same run. With no address published, the address half of that match could not be exercised, so we make no absence claim from it.
The 5 pages we read — all on
- Semaglutide page
Semaglutide Rx From $149 $249 /first mo.
- Tirzepatide page
Tirzepatide Rx From $199 $315 /first mo.
- Nad page
NAD+ Rx From $99 $179 /first mo.
- Sermorelin page
Sermorelin Rx From $125 $225 /first mo.
- Treatments page
WEIGHT LOSS GLP-1 Semaglutide Injectable · Weekly From $149/mo Get Started Explore WEIGHT LOSS Tirzepatide Injectable · Weekly · Dual GIP/GLP-1 From $199/mo
This link pays us nothing. It's here because the price is checkable.
Alternatives to Zera Health
| Provider | Grade | Cheapest price |
|---|---|---|
| Vita Bella | CCaveat | $109/mo |
| Nu Image Medical | CCaveat | $99/mo |
| QuickMD | BMinor gap | $99/mo |
| Red Mountain Weight Loss | FFail | $99/mo |
| Zappy Health | BMinor gap | $99/mo |